Ataraxis ASCO 2026 Presentation Schedule
Ataraxis is heading to ASCO 2026 with new predictive data supporting our first-in-class tools. For the first time, we're presenting clinical evidence that AI can predict treatment benefits of adjuvant and neoadjuvant therapies in breast cancer on an individual basis, rather than relying on population averages and overall cancer aggressiveness. We will present our first clinical validation in a Phase III randomized controlled trial and results of a prospective trial of Ataraxis Breast.
Poster Presentations on June 1, 1:30 PM–4:30 PM CDT
Poster 551, Board 36: Estimating Individual Benefit from Adjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer Using Causal Multimodal Artificial Intelligence
- Presenter: Dr. Frederick Howard, UChicago Medicine
Poster 550, Board 35: Evaluating Performance of an AI-Based Recurrence Score in Early Breast Cancer Patients Treated with Chemoendocrine Therapy: A Secondary Analysis of the UNIRAD Trial
- Presenter: Dr. Thomas Bachelot, Centre Léon Bérard
Poster 534, Board 19: Real-World Deployment of a Multimodal AI Model for Predicting Response to Neoadjuvant Therapy in Early Breast Cancer
- Presenter: Dr. Bareket Daniel, Shaare Zedek Medical Center
Poster 552, Board 37: Evaluating the Prognostic Performance of an AI-Based Model in Clinically Low-Risk HR+/HER2- Early Breast Cancer
- Presenters: Dr. Dhruva Biswas, Ataraxis AI